Mesenchymoangioblast (MB) is the earliest precursor for endothelial and mesenchymal cells originating from APLNR + PDGFRα + KDR + mesoderm in human pluripotent stem cell cultures. MBs are identified based on their capacity to form FGF2-dependent compact spheroid colonies in a serum-free semisolid medium. MBs colonies are composed of PDGFRβ + CD271 + EMCN + DLK1 + CD73 − primitive mesenchymal cells which are generated through endothelial/angioblastic intermediates (cores) formed during first 3-4 days of clonogenic cultures. MB-derived primitive mesenchymal cells have potential to differentiate into mesenchymal stromal/stem cells (MSCs), pericytes, and smooth muscle cells. In this review, we summarize the specification and developmental potential of MBs, emphasize features that distinguish MBs from other mesenchymal progenitors described in the literature and discuss the value of these findings for identifying molecular pathways leading to MSC and vasculogenic cell specification, and developing cellular therapies using MB-derived progeny.
Introduction
Mesenchymal tissues are critical components of any organ in the human body, including vasculature. Although mesenchymal cells within many organs share a common phenotype and capacity to grow in adherent cultures, they are comprised of functionally and developmentally diverse cell populations. Recent advances in human pluripotent stem cell (hPSC) technologies have demonstrated the feasibility of generating different types of mesenchymal cell populations, including mesenchymal stroma/stem cells (MSCs), pericytes (PCs), and smooth muscle cells (SMCs) de novo. However, applying hPSC-derived mesenchymal cells for studying mesenchymal cell development, cellular therapies, and tissue engineering is hampered by the lack of knowledge regarding a mesenchymal progenitor hierarchy and markers that allow to discriminate different mesenchymal cell populations. Identification of a common mesodermal progenitor for mesenchymal and endothelial cells, mesenchymoangioblast (MB), was an important milestone toward solving these problems [1] . The purpose of this review is to summarize our current knowledge of MBs and their differentiation potential, and to discuss the implications of these 1 3 findings for studies mesenchymal cells and development of novel cellular therapies.
Mesenchyme formation during embryonic development
During embryonic development, the connective tissues, including bone, cartilage, adipose, blood cells, and vasculature are derived from mesenchyme. The formation of embryonic mesenchyme is one of the most critical events during embryogenesis that leads to the establishment of cardiovascular, hematopoietic, skeletal, and soft tissues. During gastrulation, the first mesenchymal cells forming primitive streak arise from epiblast through epithelial-to-mesenchymal transition. Following differentiation and migration, primitive mesenchymal cells partition into three major components forming lateral plate, intermediate, and paraxial mesoderm [2] [3] [4] [5] . In addition, the earliest mesenchymal cells transgressing through the primitive streak give rise to extraembryonic mesoderm that forms yolk sac and allantois tissues. Another, relatively smaller portion of mesenchyme is produced from neural crest that originates from ectoderm at the margins of neural tube. Mesenchymal cells derived from neural crest produce craniofacial connective tissues, while connective tissues in the body are predominantly of mesodermal origin [6] [7] [8] . Although in vivo lineage mapping experiments in avian and mouse have extensively characterized germ layer contributions to mesenchymal derivatives, including bone marrow MSCs, smooth muscle cells (SMC), and pericytes (PCs), and have demonstrated the mosaic origin of mural cells and MSCs within vasculature and bone marrow as related to the site of origin [9] [10] [11] [12] [13] , the hierarchy of mesenchymal progenitors formed during early stages of embryogenesis remains poorly understood. Moreover, due to fundamental developmental differences between mouse and human [14] , it is critical to assess how mesenchymal cells develop in human ontogeny.
Development of MB defines the onset of mesenchymo-and endotheliogenesis in human pluripotent stem cell cultures
Discovery of hPSCs, including embryonic stem cells (hESCs) [15] and induced pluripotent stem cells (hiPSCs) [16, 17] , opens opportunities to produce de novo SMCs and PCs [18] [19] [20] [21] , obtains the earliest mesodermal/mesenchymal populations, otherwise inaccessible in humans, and assesses the most primitive stages of embryonic development in vitro. Using hPSCs directed toward mesendodermal differentiation, Vodyanik et al. [1] revealed a novel clonal progenitor for endothelial and mesenchymal cells, designated as MB by analogy with hemangioblast (HB), a common progenitor for endothelial and hematopoietic cells. MBs were identified by their capacity to form compact spheroid colonies in FGF2-supplemented semisolid medium, which are capable of differentiating into endothelial and mesenchymal cells [1] . Formation of MB colonies solely depends on FGF2, but not other factors (VEGF, SCF, IGF1, EGF, and HGF), and requires serum-free medium [1] . Addition of PDGF-BB to FGF2-supplemented clonogenic medium enhances the frequency and size of MB colonies. However, PDGF-BB alone was not sufficient to support MB colony formation. In contrast, TGFβ1 or activin A completely abrogates MB colony formation.
MBs appear very early and exist only transiently during differentiation. In coculture with OP9, or in chemically defined conditions, MBs emerge on day 2 of differentiation from a mesodermal population expressing apelin receptor (APLNR), PDGFRα and KDR [1, 22] . MB colonies are dramatically reduced on day 3 of differentiation and entirely disappear on day 4 of differentiation. MBs precede development of HBs [1, 22] , thereby suggesting that MB is the earliest clonogenic mesodermal progenitors to mark the onset of endothelio-and mesenchymogenesis in hPSC cultures.
MB generates mesenchymal cells through endothelial intermediates
Using time-lapse imaging, single cell deposition assay, and chimeric hESC lines containing equal proportions of EGFP and mOrange-marked H1 hESCs, we demonstrated a single cell origin of MB colonies. In addition, time-lapse microscopy revealed unique morphogenic events involved in MB colony formation [1] . When placed in clonogenic medium with FGF2, mesodermal cells from day 2 hESC differentiation cultures exhibit high motility. Following several divisions, a single mesodermal cell forms an immotile structure (core) composed of approximately 30 cells expressing KDR and typical endothelial genes, including PECAM and CDH5 (day 3 of clonogenic culture). Subsequently, cells at the core periphery undergo endothelial-to-mesenchymal transition (EndMT) and form a shell of tightly packed mesenchymal cells that continue to expand for up to 12-14 days of clonogenic culture (Fig. 1) . Interestingly, the aggregation of migrating gastrulating cells and KDR upregulation in response to FGF produced by endoderm was also observed in chicken embryo [23, 24] , thereby suggesting that morphogenic events observed during early stages of MB colony formation in FGF2 supplemented clonogenic culture from day 2 differentiated hPSCs resemble angioblast formation in vivo.
To analyze the differentiation potential of MB colonies at different stages of development, we isolated individual colonies on days 3, 6, and 12 of clonogenic culture and assessed endothelial and mesenchymal cell generation in coculture with OP9 [1] . These studies revealed that 3-day-old colonies (core stage) formed primarily endothelial clusters, while day 12 colonies formed predominantly mesenchymal clusters. In contrast, day 6 colonies primarily formed mesenchymoendothelial clusters, i.e., clusters composed of both endothelial and mesenchymal cells. Overall, these observations demonstrate that MB generates mesenchymal cells through endothelial/angioblastic intermediates and provides the direct link between endothelio-and mesenchymogenic populations. We have found that MB appears in hPSC cultures committed to mesendoderm differentiation on day 2 of culture along with upregulation of APLNR [1] , which is typically expressed in primitive streak and adjacent embryonic and extraembryonic mesoderm, and later in lateral plate mesoderm [29] [30] [31] . Sorting experiments revealed that MB colony-forming cells almost entirely segregate to the APLNR + fraction [1] . Phenotypic analysis of APLNR + cells on day 2 of differentiation demonstrated that they express other primitive streak and early mesodermal markers PDGFRα and KDR [32] [33] [34] , but no typical endothelial, MSCs, and hematopoietic markers (CD73, VE-cadherin, CD31, CD43 and CD45 endothelial, MSCs, and hematopoietic markers [35, 36] . Molecular profiling of APLNR + cells revealed expression of MIXL1, T, and EOMES primitive streak genes and FOXF1, HAND1, HAND2, IRX3, BMP4, and WNT5A genes typically found in lateral plate/extraembryonic mesoderm, but not note genes associated with neural crest, endoderm, paraxial, and intermediate mesoderm, thereby indicating that MB arises from a cell population that resembles very early primitive posterior mesoderm in the gastrulating embryo [1] .
MBs give rise to different mesenchymal cell lineages
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MB differentiation and MB colony development in clonogenic cultures proceed through two discrete stages: (1) formation of a core composed of tightly adherent endothelial-like angiogenic cells and (2) development of mesenchymal progenitors from endothelial cores through EndMT (Figs. 1, 3 Mesenchymal progenitors forming MB colonies can be discriminated by surface expression of primitive mesenchymal markers CD271, Endomucin and delta-like noncanonical Notch ligand 1 (DLK1), and lack of the typical MSC marker CD73 [1, 25] . In addition, our molecular profiling studies of mesenchymal cells throughout all stages of specification and diversification revealed that MB colonies uniquely express HAND1, TBR1, and LHX genes [25] that are involved in tissue morphogenesis and PRRX1 gene known to be present in the primitive bone marrow mesenchymal progenitors [38] . PDGFRβ + CD271 + EMCN + DLK1 + CD73 − primitive mesenchymal cells from MB colonies can be differentiated into MSCs and juvenile proliferative imPCs and imSMCs following treatment with molecules involved in specification of these mesenchymal lineages (Figs. 2, 3 ). This transition is associated with acquisition of mesenchymal marker CD73, which is expressed by all types of differentiated mesenchymal cells, including MSCs, PCs, and SMCs [25] . imPCs generated from MBs can be further specified into NG2 + SMA − capillary (PC1) and NG2 + SMA + arteriolar (PC2) PCs, while immature/synthetic SMCs can be induced to differentiated into MYH11 + contractile SMCs (Figs. 2, 3 ). Distinguishing between PCs and SMCs could be made based on the expression of NG2 and calponin. All PC populations express NG2 and low levels of calponin, while lacking NG2 and high calponin expression could be used to define SMCs. MSCs typically do not express NG2 and calponin. In addition, expression of MYOCD gene is very specific for imSMCs and helps to discriminate these cells from imPCs and MSCs. When MB-derived imSMCs transition into contractile mSMCs, they upregulate expression of MYH11 protein, a very specific marker of mature SMCs.
Molecular profiling studies MB-derived PCs revealed that capillary PC1 generated from MBs has a "proinflammatory" gene expression profile as signified by high levels of chemoattractants, inflammatory, VCAM1, and programmed cell death ligand PDL1 (CD274), gene expression. In contrast, arteriolar PC2 could be distinguished by high expression of DLK1, which is found to be expressed by fetal arteriolar PCs [39] . Based on these findings, the utility of flow cytometric analysis for phenotypic discrimination between CD274 + VCAM high capillary PC1 and DLK1 + arteriolar PC2 was demonstrated [25] .
Interestingly, CD146 or MCAM, which is typically used to isolate PCs from somatic tissues [40] , is expressed at all stages of mesenchymal development, including MB colonies and all differentiated mesenchymal cells [25] , thereby suggesting the limited utility of this marker for identifying mural cell populations in hPSC cultures.
Overall, these studies have defined the hierarchy of mesoderm-derived mesenchymal cells in hPSC cultures and established a platform for studying the molecular pathways guiding mesenchymal cell specification. In addition, mesenchymal cell differentiation through a well-defined clonogenic progenitor stage, followed by directed specification of primitive mesenchymal intermediates to a particular mesenchymal lineage, makes it possible to generate pure populations of MSCs, PCs, and SMCs for tissue engineering and cellular therapies.
Distinguishing MBs from other types of embryonic mesenchymal progenitors
Mesoangioblast
Mesoangioblasts were initially described as expandable cell lines generated from dispersed E9.5 embryonic mouse aorta cells by limiting dilution [41] . Mesoangioblast cell lines express endothelial Cd34, Flk1, and Cdh5 genes with some cells within cell lines showing SMA protein expression. Embryonic mesoangioblasts have capacity to differentiate into osteoblasts, adipocytes, cartilage, cardiomyocytes, skeletal and smooth muscle, osteoclasts, and macrophages [41] . Later mesoangioblast terminology was also applied to mesenchymal or pericyte-like alkaline phosphatase positive cells isolated following 7 day culture of minced skeletal muscle cells on collagen type I-coated plates [42] . It has been shown that these cells have a capacity to differentiate into skeletal muscle in vitro and incorporate into skeletal muscles following in vivo transplantation [43] [44] [45] . In addition, the term "mesoangioblast" is used to describe hPSC-derived fibroblastoid cells that were reprogrammed into skeletal muscle cells with MYOD1 [46] , a transcription factor that directly coverts fibroblasts and PSCs into skeletal muscle cells [47] [48] [49] [50] . Since no single marker was identified that denotes mesoangioblasts across different stages of development and species, it was concluded that mesoangioblasts are primarily defined by their isolation method and functional properties [51] .
In 
Hemangioblast and cardiovascular clonogenic mesodermal progenitors
Flk1
+ (KDR + ) mesodermal cells emerging within primitive streak possess a broad differentiation potential. In addition to MBs, Flk1 + cells contain clonogenic progenitors with hematopoietic (HB) and cardiac potentials [52] [53] [54] . HB, a mesodermal progenitors with capacity to form colonies composed of immature (blast) hematopoietic cells in semisolid medium supplemented with VEGF, SCF, and conditioned medium from the endothelial cell line D4T, was initially identified in mouse embryonic stem cell (ESC) differentiation cultures [55] . Later studies revealed that blast colony-forming cells (BL-CFCs) also possess capacity to generate endothelial cells [56] , leading to the conclusion that BL-CFCs represent a common precursor for endothelial and hematopoietic cells, HB. In addition, in vivo studies revealed BL-CFCs in the Flk1 + posterior primitive streak of E7.5 mouse embryo [52] , thereby providing evidence that HB exists in vivo. Interestingly, formation of HB colonies in clonogenic medium similar to MBs proceeds through endothelial intermediates [1, 57] . However, in contrast to MBs, endothelial intermediates in HB colonies undergo endothelial-to-hematopoietic transition and form blood. It has been shown that cells collected from clonogenic HB cultures from hESCs generate MSCs [58] . However, it remains unclear whether MSCs generated by this method originate from HBs, MBs or other types of mesenchymal progenitors which are commonly formed along with HBs in semisolid colony-forming cultures [1, [59] [60] [61] . Thus, a conclusion regarding MSC potential of HBs can be made only by analyzing individual HB colonies. When we collected individual HB colonies and cultured them on fibronectin/ collagen-coated plates in presence of FGF2, we failed to generate MSCs (data not published), thereby suggesting that HB is an unlikely source for MSCs. Flk1 + cells with cardiac CFC potential in posterior primitive streak and ESC cultures, were detected in semisolid medium supplemented with cytokines known to function in mesoderm and early heart formation, including VEGF, FGF2, BMP4, and the Wnt inhibitor, DKK1 [53, 62] . In these conditions, mesodermal cells form tightly packed colonies expressing an array of cardiac markers and capable of spontaneous contraction when replated on gelatin substrate in serum-free medium. Gene expression analysis of expanded cardiac colonies revealed that they express endothelial PECAM and CDH5 and SMC SMA and CNN1 genes, suggesting that cardiac colonies may have endothelial and SMC potential [53] . However, in contrast to MB colonies, cardiac colonies and cells expanded from these colonies express TBX5, TNX20, and MYL2 cardiac genes [53, 54] . HBs and cardiovascular colony-forming progenitors are transient progenitors similarly to MBs. In PSC cultures, clonogenic mesodermal progenitors emerge in well-defined temporary order: MB colonies appears first, typically on day 2 differentiation [1, 22] , HBs emerges next, typically on day 3 of differentiation [1, 35, 63] , and cardiac colonies are formed a day later following HBs [53, 62] . Thus, mesodermal clonogenic progenitors within the Flk1 + population can be distinguished not only by functional properties, but distinct temporal kinetics during differentiation.
Mesospheres and other types of mesenchymal progenitors
Studies by Elefanty's group [59] revealed that addition of WNT3A to HB clonogenic cultures inhibited formation of HB colonies and promoted development of mesodermal colonies termed, mesospheres. Mesospheres display a morphology and gene expression profile similar to MB colonies and could differentiate into adipocytes, osteocytes and SMCs. However, in contrast to MBs, mesospheres develop in presence of VEGF [59] , which blocks formation of MB colonies at angiogenic core stage [1, 64] . Currently, it remains unclear whether mesospheres represent MB or a distinct mesenchymal progenitor. One can argue that differences in mesenchymal colony-forming potential in presence of VEGF indicate that mesospheres and MBs are different progenitors. On the other hand, it is possible that addition of WNT3A to clonogenic cultures may overcome VEGF-mediated inhibition of endothelial-to-mesenchymal transition and allow for MB colony formation in presence of VEGF.
Vasculogenic potential of Flk1 + cells was initially described by Yamashita et al., [65] 
MB potential for cellular therapies
Mesenchymal cells for tissue repair and regeneration
MSCs and perivascular cells isolated from adult tissues are recognized as a promising cell source for tissue regeneration. MSCs have capacity to differentiate into bone and cartilage and regenerate corresponding tissues directly. In addition, MSCs and perivascular cells can regenerate tissues indirectly by suppressing inflammation, stimulating angiogenesis, and recruiting tissue-specific progenitors to the site of injury (reviewed in Refs. [68] [69] [70] ). MSCs also exhibit potent immunosuppressive activities, which are at least partially mediated by signaling activated by MSC apoptosis following infusion [71] . MSC treatments for a variety conditions have been pursued in numerous clinical trials, including bone and cartilage healing, cardiovascular regeneration, and graft-versus-host disease (GVHD), a major complication following allogeneic hematopoietic stem cell transplantation [70, 72, 73] . Although multiple protocols for generating mesenchymal cells from hPSCs have been described (reviewed in Refs. [79] [80] [81] ), origin and heterogeneity of mesenchymal cell populations obtained in these studies has not been addressed. Typically, hPSC-MSC protocols rely on selective expansion of fibroblastoid cells, which were spontaneously differentiated from hPSCs in presence of feeders, serum, or platelet lysate, or following treatment with TGFβ inhibitor. In some studies, fibroblastoid cells were isolated from differentiation cultures using CD105, CD73, or CD146 markers that are expressed by all types of mesenchymal lineages, including MSCs, SMCs and PCs. It is highly likely that the spontaneous differentiation process generates a mixture of functionally diverse mesenchymal cells of unknown embryonic origin and at different stages of development, which limits its utility for reproducible generation of pure mesenchymal cell populations for clinical use. Thus, developing well-defined progenitor-based protocols and identifying markers allowing to discriminate functionally distinct mesenchymal populations would be very critical to achieve standardization of hPSC-derived mesenchymal cell products.
The safety issues related to hPSC-derived MSCs are of paramount significance. Since MSCs are administered in relatively high numbers, the presence of even small numbers of undifferentiated hPSCs raises concern for potential teratoma formation (reviewed in Refs. [82] [83] [84] ). It is also important to ensure the genomic integrity and epigenetic stability of iPSC lines used for mesenchymal cell manufacturing. Initially, iPSCs were generated using retroviral vectors in which transgenes are permanently integrated into the genome. However, within a short period of time, transgenefree reprogramming technologies have been developed, including episomal plasmids, modified RNA, Sendai virus, and protein-based methods (reviewed in Ref. [85] ). It has been demonstrated that most genomic variations observed in iPSCs are inherited from the cells of origin and are not related to reprogramming [86] [87] [88] . Nevertheless, the possibility of de novo generation of genomic aberrations during reprogramming process cannot be entirely excluded [89] . Genomic instability can also occur following long-term expansion and differentiation of hiPSCs [90] [91] [92] . Therefore, careful monitoring genome integrity of hiPSCs and their derivatives is required to ensure hiPSC-MSC safety in clinical applications.
Benefits of using MB-based protocol for clinical grade MSC and perivascular cell generation
Mesenchymal cells generation through MB progenitor pathway using defined steps directing MBs to MSCs, PCs, or SMCs allows for the production of pure well-defined mesenchymal cell populations and standardization of the cell manufacturing process. Since semisolid medium used for generating MB colonies does not support the growth of singularized undifferentiated hPSCs, this step permits not only selection of primitive mesenchymal progenitors, but also effective elimination of undifferentiated hPSCs that pose a tumorigenicity risk. MSC products obtained from MBs are naturally free of immune cells, including macrophages, because MBs emerge in cultures before HBs and blood cells are formed. This prevents any possibility of adverse immunologic reaction to MSC products due to presence of contaminating immune cells.
MSCs generated from MBs have a robust expansion potential. Up to 10 22 MSCs can be generated from a single MB colony, following continuous expansion for 120 days in culture [1] . Given that hPSC lines are capable of growing indefinitely in culture and can be expanded up to 10 72 fold [93] , essentially unlimited number of MSCs can be generated from a single hPSC line obtained from a single donor. It has been shown that MSCs isolated from adult tissues lose their therapeutic properties following prolonged in vitro culture making scaling of adult MSC products difficult [94, 95] . In contrast, MB hPSC-based protocol eliminates the need for excessive MSC expansion and allows for scalable manufacturing of low passage MSCs to meet the clinical needs for young cell products.
MBs can be efficiently differentiated in chemically defined conditions from hPSCs, which were also expanded in chemically defined conditions [22, 96] . Protocols for generating MB colonies and MSCs require serum-and xenogenfree conditions [1] . Therefore, all MSC differentiation steps through the MB pathway can be easily adopted for good manufacturing practice (GMP). In addition, the MB platform can be adopted for cell-mediated drug delivery. hPSCs can be genetically modified using CRISPR/Cas9 to express therapeutic molecules and clonally selected, thereby ensuring homogeneity of genomic editing and eliminating clones with deleterious off-target effects. Subsequently engineered hPSC lines can be used to produce an unlimited number of drug-loaded MSCs.
Overall, the MB-based platform for MSC production eliminates donor-to-donor variability, establishes the consistency in a product and its manufacturing process, and makes feasible a low cost/high volume manufacturing of an unlimited off-the-shelf supply of well-defined drug-like cellular products.
Experimental therapies with MB-derived MSCs
Within the last decade, several animal studies have demonstrated the therapeutic efficacy of hESC and hiPSC-derived MSCs in animal models of bone and cartilage injury, autoimmune and inflammatory diseases, myocardial infarction, and pulmonary injury (reviewed in Ref. [79] ). Interestingly, hESC-derived MSCs performed more effectively compared to bone marrow MSCs in reducing experimental autoimmune encephalitis [97] , pulmonary hypertension [98] , and acute pulmonary injury [99] , and hiPSC-derived MSCs outperformed bone marrow MSCs in a mouse model of anthracycline-induced cardiomyopathy [100] . MB-derived MSCs have already been tested mouse models of hindlimb ischemia and chronic airway disease. In hindlimb ischemia, intramuscular injection of MB-derived MSCs inhibited 1 3 tissue damage, improved peripheral blood flow and significantly reduced toe necrosis, suggesting that these cells have a significant protective effect against ischemic insult [101] . Royce et al. [102] , induced chronic allergic airways disease (AAD)/asthma by administering aerosolized ovalbumin to ovalbumin-sensitized mice. After establishing chronic AAD, mice were treated with MSCs administered intravenously or intranasally. Both intravenous and intranasal MB-derived MSC administration protected from airway inflammation, airway remodeling including goblet cell metaplasia, excessive fibroblast proliferation and collagen deposition, and airway hyperresponsiveness. It was also noted that intranasal MSC administration directly to the lungs offered greater protection against ovalbumin-induced airway remodeling and hyperresponsiveness. The immunomodulatory effect of MB-MSCs was greater than bone marrow or adipose MSCs.
Concluding remarks
During development, mesenchymal cells originate from multiple mesodermal and neural crest sources, which dictates their functional heterogeneity and complicates the process of generating well-defined pure mesenchymal cell populations from hPSCs. Discovery of MBs as the earliest clonogenic mesodermal progenitor for mesenchymal cells was a critical first step that permitted selection and interrogation of mesenchymal lineages originating from a single mesodermal cell with distinct clonogenic properties. Moreover, demonstration that MBs generate mesenchymal cells through endothelial/angioblastic intermediates, provided clear evidence of a direct developmental link between endothelial and mesenchymal progenitor populations. The recent identification of sequential stages of MB differentiation toward MSCs, PCs, and SMCs, in addition to novel stage-and lineage-specific markers, created a platform for exploring the molecular mechanisms guiding specification and diversification of mesenchymal lineages of mesodermal origin and modeling genetic diseases associated with vascular and skeletal abnormalities using patient-specific iPSCs. The MB-based protocol for SMC differentiation provided access to well-defined synthetic and contractile SMC populations, thus offering an in vitro system to study mechanisms of neointimal hyperplasia and drug testing for conditions associated with dysregulation of vascular SMC proliferation.
Despite progress with understanding mesenchymal cell specification through the MB pathway, the complexity mesenchymal cell development in hPSC cultures remains poorly understood. Mesenchymal cell generation from neural crest and different mesodermal compartments [10, 21] and cardiovascular clonogenic progenitors [53, 54] has been demonstrated. However, the distinct developmental stages and progenitors formed in these conditions remain uncharacterized. Thus, further studies are needed to decipher mesenchymal cell genesis of various origins at the progenitor level.
Comparing the phenotype and function of developmentally diverse mesenchymal cell populations will be essential for better understanding the vascular and skeletal lineages in development and diseases states. It may also aid in designing cellular therapies that better meet specific clinical needs.
hPSCs are a logical alternative source of mesenchymal cells for cellular therapies and tissue engineering. MB-based mesenchymal cell generation protocols, in contrast to protocols based on spontaneous hPSC differentiation, allow for standardized manufacturing of well-defined pure MSC, PC, and SMC cell populations for clinical applications. The therapeutic efficacy of MB-derived MSCs has been demonstrated in animal models of hindlimb ischemia and chronic allergic airways disease [101, 102] . Further animal and in vitro studies are needed to compare the therapeutic potential of MB-derived MSCs and various PC subsets, to explore whether more specific and efficient targeting of inflammation versus tissue degeneration could be achieved with these populations. imPCs and capillary PC1 demonstrated superior vessel-stabilizing potential in vitro and in vivo [25] , suggesting that these PCs could be more efficient in treating tissue damage associated with vascular diseases. Comparative analysis of the immunosuppressive properties of distinct MB-derived mesenchymal populations may help to design better cellular therapies for GVHD and autoimmune diseases. Finally, advances in gene editing technologies have created opportunities for using MB-derived MSCs as a vehicle for drug delivery, which can be manufactured in unlimited quantities. Further exploration of these technologies in preclinical studies will be essential for advancing the field.
iPSC-derived MSCs already reached clinical translation. Recently, Australian stem cell and regenerative medicine company, Cynata Therapeutics has conducted the first phase I clinical trial to evaluate safety and efficacy of allogeneic MB-derived MSCs for treating steroid resistant GVHD (NCT02923375). Interim data from 8 patients in this trial revealed the overall response rate 100% and complete response rate 50% without treatment-related serious events during a primary evaluation period (100 days posttreatment). This milestone already made important inroads to moving iPSC-based MSC technologies into clinic. 
